The contraceptive vaginal ring, NuvaRing^®, a decade after its introduction

References

• Rosenberg MJ, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999;180:276–9.
   PubMed Web of Science ®Google Scholar
• Barnhardt KT, Timbers K, Pretorius ES, . In vivo assessment of NuvaRing® placement. Contraception 2005;72:196–9.
   PubMed Web of Science ®Google Scholar
• Sivin I, Mishell DR Jr, Alvarez F, . Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: A 1-year dose-finding trial. Contraception 2005;71:122–9.
   PubMed Web of Science ®Google Scholar
• Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception 2010; 82:428–34.
   PubMed Web of Science ®Google Scholar
• Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001;75:865–70.
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Mulders TMT. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233–42.
   PubMed Web of Science ®Google Scholar
• van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168–74.
   PubMed Web of Science ®Google Scholar
• Roumen FJME, Dieben TOM. Comparison of uterine concentrations of ethinylestradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. Fertil Steril 2006;85:57–62.
   PubMed Web of Science ®Google Scholar
• Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002;17:2594–9.
   PubMed Web of Science ®Google Scholar
• Haring T, Mulders TMT. The combined contraceptive ring NuvaRing® and spermicide co-medication. Contraception 2003;67:271–2.
   PubMed Web of Science ®Google Scholar
• Verhoeven CHJ, Dieben TOM. The combined contraceptive vaginal ring, NuvaRing®, and tampon co-usage. Contraception 2004;69:197–9.
   PubMed Web of Science ®Google Scholar
• Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet 2005;44:429–38.
   PubMed Web of Science ®Google Scholar
• Verhoeven CHJ, van den Heuvel MW, Mulders TMT, Dieben TOM. The contraceptive vaginal ring, NuvaRing®, and antimycotic co-medication. Contraception 2004;69:129–32.
   PubMed Web of Science ®Google Scholar
• Ahrendt HJ, Nisand I, Bastianelli C, . Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74:451–7.
   PubMed Web of Science ®Google Scholar
• Dieben TOM, Roumen FJME, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100:585–93.
   PubMed Web of Science ®Google Scholar
• Oddsson K, Leifels-Fischer B, de Melo NR, . Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: A 1-year randomized trial. Contraception 2005;71:176–82.
   PubMed Web of Science ®Google Scholar
• Roumen FJME, Apter D, Mulders TMT, Dieben TOM. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001;16:469–75.
   PubMed Web of Science ®Google Scholar
• Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing®: Results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008;13:31–8.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Hund M. Clinical experience with NuvaRing® in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007; 12:240–7.
   PubMed Web of Science ®Google Scholar
• Roumen FJME, op ten Berg MMT, Hoomans EHM. The combined contraceptive vaginal ring (NuvaRing®): First experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006;11:14–22.
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch KE, Darensbourg C, Ogden B, . Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive. Contraception 2007;76:348–56.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, . Route of administration of contraceptives containing desogestrel/etonogestrel and insulin sensitivity: A prospective randomized study. Contraception 2009;80:34–9.
   PubMed Web of Science ®Google Scholar
• Guazzelli CAF, Barreiros FA, Torloni MR, Barbieri M. Effects of extended regimens of the contraceptive vaginal ring on carbohydrate metabolism. Contraception 2012;85:253–6.
   PubMed Web of Science ®Google Scholar
• Mohamed AMM, El-Sherbiny WSM, Mostafa WAI. Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone). Int J Gynecol Obstet 2011;114:145–8.
   PubMed Web of Science ®Google Scholar
• Tuppurainen M, Klimscheffskij R, Venhola M, Dieben TOM. The combined contraceptive vaginal ring (NuvaRing®) and lipid metabolism: A comparative study. Contraception 2004;69:389–94.
   PubMed Web of Science ®Google Scholar
• Barreiros FA, Guazzelli CAF, Barbosa R, . Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: Effects on lipid metabolism. Contraception 2011;84:155–9.
   PubMed Web of Science ®Google Scholar
• Duijkers I, Killick S, Bigrigg A, Dieben TOM. A comparative study on the effects of a contraceptive vaginal ring NuvaRing® and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2004;9:131–40.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Plu-Bureau G, Menard J, . Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab 2007;92:2074–9.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Burke AE, Barnhart KT, . Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception 2008;78:451–8.
   PubMed Web of Science ®Google Scholar
• Fleischer K, van Vliet HA, Rosendaal FR, . Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: A cross-over study. Thromb Res 2009;123:429–35.
   PubMed Web of Science ®Google Scholar
• Mishell DR, Jr., Guillebaud J, Westhoff C, . Combined hormonal contraceptive trials: Variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. Contraception 2007;75:4–10.
   PubMed Web of Science ®Google Scholar
• Mishell DR, Jr., Guillebaud J, Westhoff C, . Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception 2007;75:11–5.
   PubMed Web of Science ®Google Scholar
• Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev (Online) 2008:CD003989.
   Google Scholar
• Bruni V, Pontello V, Luisi S, Petraglia F. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing®. Eur J Obstet Gynecol Reprod Biol 2008;139:65–71.
   PubMed Web of Science ®Google Scholar
• Oddsson K, Leifels-Fischer B, Wiel-Masson D, . Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: A randomized trial. Hum Reprod 2005;20:557–62.
   PubMed Web of Science ®Google Scholar
• Milsom I, Lete I, Bjertnaes A, . Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304–11.
   PubMed Web of Science ®Google Scholar
• Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstet Gynecol 2005;106:89–96.
   PubMed Web of Science ®Google Scholar
• Creinin MD, Meyn LA, Borgatta L, . Multicenter comparison of the contraceptive ring and patch: A randomized controlled trial. Obstet Gynecol 2008;111:267–77.
   PubMed Web of Science ®Google Scholar
• Miller L, Verhoeven CHJ, in‘t Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol 2005;106:473–82.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Smith V, Coffee A, . Frequency and management of breakthrough bleeding with continuous use of the transvaginal vaginal contraceptive ring: A randomized controlled trial. Obstet Gynecol 2008;112:563–71.
   PubMed Web of Science ®Google Scholar
• Guazzelli CAF, Barreiros FA, Barbosa R, . Extended regimens of the vaginal contraceptive vaginal ring: Cycle control. Contraception 2009;80:430–5.
   PubMed Web of Science ®Google Scholar
• Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006;74:220–3.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Barbara G, Somigliana E, . Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010;93:2150–61.
   PubMed Web of Science ®Google Scholar
• Lete I, Doval JL, Pérez-Campos E, . Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception 2008;77: 276–82.
   PubMed Web of Science ®Google Scholar
• Lete I, Pérez-Campos E, Correa M, . Continuation rate of combined hormonal contraception: A prospective multicenter study. J Women's Health 2012;21:490–5.
   PubMed Web of Science ®Google Scholar
• Lete I, Doval JL, Pérez-Campos E, . Factors affecting women's selection of a combined hormonal contraceptive method: The TEAM-06 Spanish cross-sectional study. Contraception 2007;76:77–83.
   PubMed Web of Science ®Google Scholar
• Costa AR, Palma F, Sá JL, . Impact of a women's counselling programme on combined hormonal contraception in Portugal – the IMAGINE study. Eur J Contracept Reprod Health Care 2011;16:409–17.
   PubMed Web of Science ®Google Scholar
• Bitzer J, Gemzell-Danielsson K, Roumen F, . The CHOICE study: Effect of counseling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care 2012; 17:65–78.
   PubMed Web of Science ®Google Scholar
• Merckx M, Donders GG, Grandjean P, . Does structured counselling influence combined hormonal contraceptive choice? Eur J Contracept Reprod Health Care 2011;16:418–29.
   PubMed Web of Science ®Google Scholar
• Fait T, Apetauer I. Importance of the consultation for combined hormonal contraception's choice – results of CHOICE project in Czech and Slovak Republic. Ceska Gynekol 2011;76:140–4.
   PubMedGoogle Scholar
• Gemzell-Danielsson K, Thunell L, Lindeberg M, . Comprehensive counseling about combined hormonal contraceptives changes the choice of contraceptive methods: Results of the CHOICE program in Sweden. Acta Obstet Gynecol Scand 2011;90:869–77.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Gruber IM. Intention to use a combined contraceptive method and choice after structured counseling in Switzerland. Eur J Contracept Reprod Health Care 2012;17:119–27.
   PubMed Web of Science ®Google Scholar
• Egarter C, Grimm C, Nouri K, . Contraceptive counselling and factors affecting women's contraceptive choices: Results of the CHOICE Study in Austria. Reprod Biomed Online 2012;24:692–7.
   PubMed Web of Science ®Google Scholar
• Ouellet-Hellstrom R, Graham DJ, Staffa JA, . Combined hormonal contraceptives and the risk of cardiovascular disease endpoints. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
   Google Scholar
• Lidegaard Ø, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: Follow-up study, Denmark 2001–10. BMJ 2012;344:e2990.
   PubMed Web of Science ®Google Scholar
• Dinger J, Pineda AA. Risk of VTE in users of an etonogestrel-containing vaginal ring and combined oral contraceptives.Presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting May 7, 2012. Source: OB/GYN Clinical Alert.
   Google Scholar
• Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004;104:555–63.
   PubMed Web of Science ®Google Scholar
• Guida M, Di Spiezio Sardo A, Bramante S, . Effects of two types of hormonal contraception – oral versus intravaginal – on the sexual life of women and their partners. Hum Reprod 2005;20:1100–6.
   PubMed Web of Science ®Google Scholar
• Gracia CR, Sammel MD, Charlesworth S, . Sexual function in first-time contraceptive ring and contraceptive patch users. Fertil Steril 2010;93:21–8.
   PubMed Web of Science ®Google Scholar